3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for Vera Therapeutics Inc

Vera Therapeutics (VERA) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Vera Therapeutics Inc

3rd Annual Guggenheim Healthcare Innovation Conference summary

10 Nov, 2026

Commercial launch and market opportunity

  • TRUTAKNA launched in the U.S. on July 7; 700 Patient Start Forms were reported in the first 17 weeks, with strong early physician interest.

  • Starts came from community and academic practices, mainly among prevalent patients still showing abnormal lab values on background IgAN therapies, sometimes after TARPEYO.

  • At 17 weeks, sibeprenlimab had roughly 1,000 Patient Start Forms versus 700 for TRUTAKNA; both launches were growing, with little direct sales-force competition.

  • U.S. B-cell modulator opportunity in IgAN was estimated closer to $20B than $10B; three marketed players were expected by year-end, while estimated biopsy-proven U.S. IgAN prevalence was 160,000.

  • Final phase III efficacy analysis was presented at ASN and published in the New England Journal of Medicine; speakers said the data showed the class could reshape IgAN treatment.

Clinical profile and differentiation

  • Phase III results showed GFR on TRUTAKNA versus decline on placebo; no treated patients reached transplant, dialysis, or death versus seven on placebo.

  • Atacicept was described as having a placebo-like safety profile, supported by study in thousands of patients over many years; weekly dosing uses a small-volume, at-home auto-injector.

  • Nephrologists were said to be comfortable with weekly dosing; 82 field reps reportedly had not encountered weekly administration as a prescribing objection.

  • Payer strategy is to maintain parity access rather than pursue preferred status; branded step-throughs involving FILSPARI and VANRAFIA affect the B-cell class.

Development plans and expansion

  • European regulators were aligned on the current IgAN dataset, with a European filing planned for Q1 2027; similar progress was reported in Japan.

  • Monthly dose-range study data were expected in Q4 2026, comparing three monthly doses with weekly dosing; a weekly-to-monthly cohort was expected to read out after Q1 2027.

  • Dose selection will assess PK, PD, efficacy, and safety; priorities include preserving efficacy and safety with a single auto-injector injection.

  • PIONEER is studying a broad range of IgA-mediated disease, including advanced disease, vasculitis, pediatric and transplant patients, plus primary membranous nephropathy, FSGS, and minimal change disease.

  • In membranous nephropathy, week-four data showed lower anti-PLA2R antibody concentrations and reduced proteinuria; a novel development program is under consideration.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Vera Therapeutics